| Carfilzomib | multiple myeloma, in all type of patients | vs bortezomib | death (overall survival) by 21% suggested progression or death (progression free survival PFS) by 47% suggested | ||
| Carfilzomib | vs bortezomid | ||||
| Carfilzomib | vs lenalidomide and dexamethasone alone | death (overall survival) by 21% suggested progression or death (progression free survival PFS) by 31% suggested | |||
| Carfilzomib | vs low-dose corticosteroids |
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
